HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts
NCT ID: NCT02551887
Last Updated: 2016-03-11
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
647 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-02-28
Study Completion Date
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary, Secondary, and Exploratory Objective(s):
Primary objective: To evaluate the effect of interventions on 1st dose uptake of HPV vaccine.
Primary objective: To evaluate the effect of interventions on 1st dose uptake of HPV vaccine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers
NCT01087164
Human Papillomavirus Infection
UNKNOWN
NA
A Pilot Study Comparing the Effectiveness of Campus Intervention to Increase HPV Vaccine Rate Among College Aged Men
NCT02508701
Human Papilloma Virus, Male
TERMINATED
NA
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
NCT02546752
Human Papilloma Virus Infection Type 11
Human Papilloma Virus Infection Type 16
Human Papilloma Virus Infection Type 18
+2 more
COMPLETED
EARLY_PHASE1
Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination
NCT03501992
Papillomavirus Vaccines
COMPLETED
NA
HPV Vaccine Hesitancy Among Indiana Youth With Cancer and Blood Diseases
NCT04667702
Human Papilloma Virus Vaccine Hesitancy
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Rationale:
Human papillomavirus (HPV) vaccine uptake among females and males remains unacceptably low. Health care provider recommendation of HPV vaccine is a major driver of vaccine acceptance. Conversely, the failure of health care providers to recommend HPV vaccine has repeatedly been identified as the primary factor in non-vaccination. Among many recommendations for increasing HPV vaccination rates are several that specifically target health care providers. Two approaches are implementation of electronic health records-based decision support systems and interventions designed to help physicians recommend HPV vaccine in a routine, matter-of-fact manner that addresses uneasiness in discussing sexual activity with parents of adolescents.
A randomized, 3-arm interventional study is proposed.
The 3 arms (randomized at the level of health care provider) will be:
1. usual practice;
2. automated reminders to recommend HPV vaccine for eligible male and female adolescents during clinic visits;
3. automated reminders PLUS a suggested recommendation script.
Here is a draft of the recommendation script that the study team is proposing for the third arm of the study: "Three vaccines are recommended for \<first name\>, meningococcal to prevent meningitis, HPV to prevent cancer, and Tdap to prevent tetanus. All three are recommended at this age". The script draft was based on the principles of Diffusion Theory and on theories of learning and memory.
Diffusion Theory predicts that adoption of an innovation (in this case the recommendation script) is predicted by three central factors:
1. The innovation should be seen as superior to the approach it is intended to replace (ADVANTAGE);
2. The innovation should be viewed as consistent with pre-existing beliefs and experiences (COMPATIBILITY); and
3. The innovation should be seen as easy to understand and implement (COMPLEXITY).
It is believed that the proposed script meets the ADVANTAGE criterion in that it provides a simple, straightforward way of introducing the HPV vaccine into conversations with adolescents and their parents, an issue with which some physicians struggle. The script meets the COMPATIBILITY criterion in that it makes the HPV vaccine recommendation consistent with the way other vaccines are typically recommended in conversations with adolescents and their parents. Finally, the proposed script meets the COMPLEXITY criterion in that it is simple and will likely be time-saving in most cases. Furthermore, the existing electronic health record (EHR) infrastructure at the target clinics will support easy introduction of the recommendation and script into clinical workflow.
Research in learning and memory has shown that information presented first or last in a sequence has the greatest salience and is therefore most likely to be remembered. In our suggested script, HPV vaccine was purposely in the middle, between Tdap and meningococcal vaccines to decrease the salience of HPV vaccination, thereby helping physicians to treat the three vaccines in a consistent manner. When HPV vaccine is mentioned last, there may be a tendency to hesitate or to treat it as separate from the other recommended vaccines.
Approximately 30 pediatric health care providers will be randomized across the 3 arms in equal numbers. The primary outcome of interest, HPV vaccination, will be evaluated as a patient outcome nested within provider. Physician acceptance of the recommendations, comparing changes in vaccination rates with qualitative feedback from providers will be further assessed. To gather qualitative feedback, 3-4 pediatric health care providers in each clinic will be interviewed. Participants will be purposely selected based on provider demographics, including gender, years in practice, and role within the clinic organizational structure. The interviews will be guided by the Consolidated Framework for Implementation Research (CFIR), a theory and evidence-based framework that represents the accumulated results of over 50 years of research on implementation and diffusion. Mixed methods will enable the team to examine not only impact on vaccination rates but also the characteristics of the reminder (e.g., usability, support of workflow), its implementation, and the context of setting in which it was implemented (e.g., clinical structure).
Aims and Objectives Aim 1. To evaluate the effects of physician-targeted automated HPV vaccination reminders alone and reminders plus a recommended script on HPV vaccination rates among 9-12 year old male and female patients.
Hypothesis. It is expected that a linear increase in HPV vaccination rates across the usual practice control group and the two intervention conditions, such that the reminder + script group will have the highest first dose HPV vaccination rates, followed by the reminder-only group will be noted.
Secondary objective: To evaluate rates of return for second dose. Exploratory objective: To evaluate experiences of pediatric health care providers with the reminder and script interventions.
Materials and Methods:
The Child Health Improvement through Computer Automation (CHICA) system, described in detail above, has already been developed and has been in operation since November of 2004. The functionality is well documented. New components of the system will have to be developed for this study. The first of these will be the activation of CHICA's ability to randomize its alerts by provider. The second will be the development of the Arden Syntax rules (Medical Logic Modules) to query the data from the immunization registry and generate appropriate prompts and reminders to the clinician. Once written, these rules must be encoded in CHICA and extensively tested with clinical data before they are deployed. Third, the study team will develop a mechanism by which CHICA can query the immunization registry at some time point after the clinic visit to determine whether an HPV vaccine was administered.
Include potential difficulties and limitations of the available methods and strategies for overcoming those methods. Randomization by physician depends on having accurate data from the clinic's registration system about which physician the patient will see. The study team has used this information in the past without significant problems. However, if it is noted that the data are missing or unreliable in a significant number of cases, the study team can ask for the information to be entered into the system by clinic personnel prior to the visit.
Programming of Arden rules is part and parcel of operating the CHICA system. So the study team does not anticipate problems with developing and testing these. The study team closely monitor the display and response to CHICA reminders. If there is a problem, the study team will be able to detect and correct it quickly.
The ability to query the CHIRP immunization registry by Health Level Seven International (HL7) messaging has recently been developed. The responses from CHIRP are not perfect, but are well over 90% reliable. The study team will build our system for querying CHIRP for HPV data to track and reissue failed queries in order to maximize the available data.
The location of the study sites. As previously noted, the study will be conducted in the five clinics in the Eskenazi Health System that currently use CHICA. They are: Eskenazi Outpatient Care Center, Blackburn, Pecar, Eskenazi 38th St., and Forest Manor.
Outcome measurement. The outcome of primary interest, HPV vaccine uptake, will be recorded by having the CHICA system re-query the CHIRP system after each visit. The study team will record whether HPV vaccine was administered. The CHICA system will be programmed to track patients who are enrolled in the study. Between 7 and 30 days after the clinic visit, CHICA will send an HL7 query for vaccination (VXQ) message for each patient to the CHIRP immunization registry of the Indiana State Department of Health. In response to this query message, CHIRP will send an HL7 vaccination record response (VXR) message with the patient's immunization record. Because all of the CHICA clinics report their immunization data to CHIRP, this will be a reliable way to assess whether the patient received an HPV vaccine.
Predictors of HPV vaccine uptake. The study team will use the re-query of CHIRP to determine which other vaccines (e.g., meningococcal; Tdap; influenza) were administered. Other variables of interest that will be recorded will be provider seen, patient age, and patient gender.
The 5 CHICA clinic study sites are located throughout metropolitan Indianapolis. These clinics serve largely low income (70% Medicaid) and minority (33% Hispanic, 49% African American) children. CHICA has provided data to over 37,000 children since first implemented in 2004. As indicated in Part 1 (Introduction), these CHICA clinics have been used successfully for multiple pediatric health service intervention studies. The real-world implementation being used in this study is a great strength. It will enable us to evaluate how a reminder system and recommended script influence HPV vaccination practices in busy pediatric clinics. An inherent limitation with this kind of study is that the study team is limited in the kind of data that can be collected. The study team cannot, for instance, collect attitude/knowledge information from parents. However, it is believed that the strengths of this research methodology far outweigh the limitations.
Qualitative interviews. Interviews will be digitally recorded and transcribed. Interviewers will be asked to record field notes related to the interview to capture information not included in the transcripts (e.g., tone of voice). Digital recordings will be transferred to a password-protected computer, in a locked office. Recordings and transcripts will be saved for a 3-year period from the end of the study. At that point in time, digital recordings and transcripts will be permanently erased. Content analysis will enable investigators to identify patterns in respondents' answers. The study team will specifically look for barriers to implementation and use of the recommendations and scripts as well as contextual aspects that facilitated routine use of the recommendations and scripts to improve adherence to recommended HPV vaccination guidelines.
Human papillomavirus (HPV) vaccine uptake among females and males remains unacceptably low. Health care provider recommendation of HPV vaccine is a major driver of vaccine acceptance. Conversely, the failure of health care providers to recommend HPV vaccine has repeatedly been identified as the primary factor in non-vaccination. Among many recommendations for increasing HPV vaccination rates are several that specifically target health care providers. Two approaches are implementation of electronic health records-based decision support systems and interventions designed to help physicians recommend HPV vaccine in a routine, matter-of-fact manner that addresses uneasiness in discussing sexual activity with parents of adolescents.
A randomized, 3-arm interventional study is proposed.
The 3 arms (randomized at the level of health care provider) will be:
1. usual practice;
2. automated reminders to recommend HPV vaccine for eligible male and female adolescents during clinic visits;
3. automated reminders PLUS a suggested recommendation script.
Here is a draft of the recommendation script that the study team is proposing for the third arm of the study: "Three vaccines are recommended for \<first name\>, meningococcal to prevent meningitis, HPV to prevent cancer, and Tdap to prevent tetanus. All three are recommended at this age". The script draft was based on the principles of Diffusion Theory and on theories of learning and memory.
Diffusion Theory predicts that adoption of an innovation (in this case the recommendation script) is predicted by three central factors:
1. The innovation should be seen as superior to the approach it is intended to replace (ADVANTAGE);
2. The innovation should be viewed as consistent with pre-existing beliefs and experiences (COMPATIBILITY); and
3. The innovation should be seen as easy to understand and implement (COMPLEXITY).
It is believed that the proposed script meets the ADVANTAGE criterion in that it provides a simple, straightforward way of introducing the HPV vaccine into conversations with adolescents and their parents, an issue with which some physicians struggle. The script meets the COMPATIBILITY criterion in that it makes the HPV vaccine recommendation consistent with the way other vaccines are typically recommended in conversations with adolescents and their parents. Finally, the proposed script meets the COMPLEXITY criterion in that it is simple and will likely be time-saving in most cases. Furthermore, the existing electronic health record (EHR) infrastructure at the target clinics will support easy introduction of the recommendation and script into clinical workflow.
Research in learning and memory has shown that information presented first or last in a sequence has the greatest salience and is therefore most likely to be remembered. In our suggested script, HPV vaccine was purposely in the middle, between Tdap and meningococcal vaccines to decrease the salience of HPV vaccination, thereby helping physicians to treat the three vaccines in a consistent manner. When HPV vaccine is mentioned last, there may be a tendency to hesitate or to treat it as separate from the other recommended vaccines.
Approximately 30 pediatric health care providers will be randomized across the 3 arms in equal numbers. The primary outcome of interest, HPV vaccination, will be evaluated as a patient outcome nested within provider. Physician acceptance of the recommendations, comparing changes in vaccination rates with qualitative feedback from providers will be further assessed. To gather qualitative feedback, 3-4 pediatric health care providers in each clinic will be interviewed. Participants will be purposely selected based on provider demographics, including gender, years in practice, and role within the clinic organizational structure. The interviews will be guided by the Consolidated Framework for Implementation Research (CFIR), a theory and evidence-based framework that represents the accumulated results of over 50 years of research on implementation and diffusion. Mixed methods will enable the team to examine not only impact on vaccination rates but also the characteristics of the reminder (e.g., usability, support of workflow), its implementation, and the context of setting in which it was implemented (e.g., clinical structure).
Aims and Objectives Aim 1. To evaluate the effects of physician-targeted automated HPV vaccination reminders alone and reminders plus a recommended script on HPV vaccination rates among 9-12 year old male and female patients.
Hypothesis. It is expected that a linear increase in HPV vaccination rates across the usual practice control group and the two intervention conditions, such that the reminder + script group will have the highest first dose HPV vaccination rates, followed by the reminder-only group will be noted.
Secondary objective: To evaluate rates of return for second dose. Exploratory objective: To evaluate experiences of pediatric health care providers with the reminder and script interventions.
Materials and Methods:
The Child Health Improvement through Computer Automation (CHICA) system, described in detail above, has already been developed and has been in operation since November of 2004. The functionality is well documented. New components of the system will have to be developed for this study. The first of these will be the activation of CHICA's ability to randomize its alerts by provider. The second will be the development of the Arden Syntax rules (Medical Logic Modules) to query the data from the immunization registry and generate appropriate prompts and reminders to the clinician. Once written, these rules must be encoded in CHICA and extensively tested with clinical data before they are deployed. Third, the study team will develop a mechanism by which CHICA can query the immunization registry at some time point after the clinic visit to determine whether an HPV vaccine was administered.
Include potential difficulties and limitations of the available methods and strategies for overcoming those methods. Randomization by physician depends on having accurate data from the clinic's registration system about which physician the patient will see. The study team has used this information in the past without significant problems. However, if it is noted that the data are missing or unreliable in a significant number of cases, the study team can ask for the information to be entered into the system by clinic personnel prior to the visit.
Programming of Arden rules is part and parcel of operating the CHICA system. So the study team does not anticipate problems with developing and testing these. The study team closely monitor the display and response to CHICA reminders. If there is a problem, the study team will be able to detect and correct it quickly.
The ability to query the CHIRP immunization registry by Health Level Seven International (HL7) messaging has recently been developed. The responses from CHIRP are not perfect, but are well over 90% reliable. The study team will build our system for querying CHIRP for HPV data to track and reissue failed queries in order to maximize the available data.
The location of the study sites. As previously noted, the study will be conducted in the five clinics in the Eskenazi Health System that currently use CHICA. They are: Eskenazi Outpatient Care Center, Blackburn, Pecar, Eskenazi 38th St., and Forest Manor.
Outcome measurement. The outcome of primary interest, HPV vaccine uptake, will be recorded by having the CHICA system re-query the CHIRP system after each visit. The study team will record whether HPV vaccine was administered. The CHICA system will be programmed to track patients who are enrolled in the study. Between 7 and 30 days after the clinic visit, CHICA will send an HL7 query for vaccination (VXQ) message for each patient to the CHIRP immunization registry of the Indiana State Department of Health. In response to this query message, CHIRP will send an HL7 vaccination record response (VXR) message with the patient's immunization record. Because all of the CHICA clinics report their immunization data to CHIRP, this will be a reliable way to assess whether the patient received an HPV vaccine.
Predictors of HPV vaccine uptake. The study team will use the re-query of CHIRP to determine which other vaccines (e.g., meningococcal; Tdap; influenza) were administered. Other variables of interest that will be recorded will be provider seen, patient age, and patient gender.
The 5 CHICA clinic study sites are located throughout metropolitan Indianapolis. These clinics serve largely low income (70% Medicaid) and minority (33% Hispanic, 49% African American) children. CHICA has provided data to over 37,000 children since first implemented in 2004. As indicated in Part 1 (Introduction), these CHICA clinics have been used successfully for multiple pediatric health service intervention studies. The real-world implementation being used in this study is a great strength. It will enable us to evaluate how a reminder system and recommended script influence HPV vaccination practices in busy pediatric clinics. An inherent limitation with this kind of study is that the study team is limited in the kind of data that can be collected. The study team cannot, for instance, collect attitude/knowledge information from parents. However, it is believed that the strengths of this research methodology far outweigh the limitations.
Qualitative interviews. Interviews will be digitally recorded and transcribed. Interviewers will be asked to record field notes related to the interview to capture information not included in the transcripts (e.g., tone of voice). Digital recordings will be transferred to a password-protected computer, in a locked office. Recordings and transcripts will be saved for a 3-year period from the end of the study. At that point in time, digital recordings and transcripts will be permanently erased. Content analysis will enable investigators to identify patterns in respondents' answers. The study team will specifically look for barriers to implementation and use of the recommendations and scripts as well as contextual aspects that facilitated routine use of the recommendations and scripts to improve adherence to recommended HPV vaccination guidelines.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Human Papilloma Virus Infection Type 11
Human Papilloma Virus Infection Type 16
Human Papilloma Virus Infection Type 18
Human Papilloma Virus Infection Type 6
Cervical Cancer
Genital Warts
Oropharyngeal Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
HEALTH_SERVICES_RESEARCH
Blinding Strategy
DOUBLE
Participants
Caregivers
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Usual Care
Usual Care Only
Group Type
NO_INTERVENTION
No interventions assigned to this group
Automated Reminder
Reminder
Group Type
ACTIVE_COMPARATOR
Automated Reminder
Intervention Type
BEHAVIORAL
Automated reminder shown to provider
Automated Reminder Plus Script
Provider sees both reminder and script.
Group Type
EXPERIMENTAL
Automated Reminder Plus Script
Intervention Type
BEHAVIORAL
Provider sees both reminder and script.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Automated Reminder
Automated reminder shown to provider
Intervention Type
BEHAVIORAL
Automated Reminder Plus Script
Provider sees both reminder and script.
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Eligible Providers
* All pediatricians and nurse practitioners who provide health care at the 5 CHICA clinics will be included in this study.
Eligible Patients
* Males and females
* 11-14 years of age with no prior HPV vaccine doses administered
* Eligible for Tdap and/or MCV4 vaccination at the visit.
* All pediatricians and nurse practitioners who provide health care at the 5 CHICA clinics will be included in this study.
Eligible Patients
* Males and females
* 11-14 years of age with no prior HPV vaccine doses administered
* Eligible for Tdap and/or MCV4 vaccination at the visit.
Exclusion Criteria
* Patients in the eligible age range who have already received one or more of the adolescent platform vaccines
Minimum Eligible Age
11 Years
Maximum Eligible Age
14 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Sponsor Role
collaborator
Indiana University
OTHER
Sponsor Role
collaborator
Regenstrief Institute, Inc.
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregory D Zimet, PhD
Role: PRINCIPAL_INVESTIGATOR
Indiana University
References
Explore related publications, articles, or registry entries linked to this study.
Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25. doi: 10.1016/j.vaccine.2006.05.111.
Reference Type
BACKGROUND
Giuliano AR, Anic G, Nyitray AG. Epidemiology and pathology of HPV disease in males. Gynecol Oncol. 2010 May;117(2 Suppl):S15-9. doi: 10.1016/j.ygyno.2010.01.026. Epub 2010 Feb 6.
Reference Type
BACKGROUND
Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010 Apr;46(4 Suppl):S20-6. doi: 10.1016/j.jadohealth.2010.01.016.
Reference Type
BACKGROUND
Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil. J Adolesc Health. 2011 Nov;49(5):467-75. doi: 10.1016/j.jadohealth.2011.07.003. Epub 2011 Sep 9.
Reference Type
BACKGROUND
Global Advisory Committee on Vaccine Safety,12-13 June 2013. Wkly Epidemiol Rec. 2013 Jul 19;88(29):301-12. No abstract available. English, French.
Reference Type
BACKGROUND
Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013 Oct 9;347:f5906. doi: 10.1136/bmj.f5906.
Reference Type
BACKGROUND
Ojha RP, Jackson BE, Tota JE, Offutt-Powell TN, Singh KP, Bae S. Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. Hum Vaccin Immunother. 2014;10(1):232-7. doi: 10.4161/hv.26292. Epub 2013 Sep 6.
Reference Type
BACKGROUND
Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, Lewis N, Deosaransingh K, Sy L, Ackerson B, Cheetham TC, Liaw KL, Takhar H, Jacobsen SJ. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012 Dec;166(12):1140-8. doi: 10.1001/archpediatrics.2012.1451.
Reference Type
BACKGROUND
Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, Dubin G; HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007 Jun;40(6):564-71. doi: 10.1016/j.jadohealth.2007.02.015.
Reference Type
BACKGROUND
Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007 Mar;26(3):201-9. doi: 10.1097/01.inf.0000253970.29190.5a.
Reference Type
BACKGROUND
Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013 Feb;40(2):130-5. doi: 10.1097/OLQ.0b013e31827bd66b.
Reference Type
BACKGROUND
Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013 Apr 18;346:f2032. doi: 10.1136/bmj.f2032.
Reference Type
BACKGROUND
Ali H, Guy RJ, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Donovan B. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis. 2013 Mar 18;13:140. doi: 10.1186/1471-2334-13-140.
Reference Type
BACKGROUND
Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years--United States, 2012. MMWR Morb Mortal Wkly Rep. 2013 Aug 30;62(34):685-93.
Reference Type
BACKGROUND
Brewer NT, Gottlieb SL, Reiter PL, McRee AL, Liddon N, Markowitz L, Smith JS. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis. 2011 Mar;38(3):197-204. doi: 10.1097/OLQ.0b013e3181f12dbf.
Reference Type
BACKGROUND
Guerry SL, De Rosa CJ, Markowitz LE, Walker S, Liddon N, Kerndt PR, Gottlieb SL. Human papillomavirus vaccine initiation among adolescent girls in high-risk communities. Vaccine. 2011 Mar 9;29(12):2235-41. doi: 10.1016/j.vaccine.2011.01.052. Epub 2011 Feb 1.
Reference Type
BACKGROUND
Liddon NC, Hood JE, Leichliter JS. Intent to receive HPV vaccine and reasons for not vaccinating among unvaccinated adolescent and young women: findings from the 2006-2008 National Survey of Family Growth. Vaccine. 2012 Mar 30;30(16):2676-82. doi: 10.1016/j.vaccine.2012.02.007. Epub 2012 Feb 15.
Reference Type
BACKGROUND
Zimet GD, Weiss TW, Rosenthal SL, Good MB, Vichnin MD. Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women. BMC Womens Health. 2010 Sep 1;10:27. doi: 10.1186/1472-6874-10-27.
Reference Type
BACKGROUND
Vadaparampil ST, Kahn JA, Salmon D, Lee JH, Quinn GP, Roetzheim R, Bruder K, Malo TL, Proveaux T, Zhao X, Halsey N, Giuliano AR. Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine. 2011 Nov 3;29(47):8634-41. doi: 10.1016/j.vaccine.2011.09.006. Epub 2011 Sep 14.
Reference Type
BACKGROUND
Evans, G. and A. Bostrom, The evolution of vaccine risk communication in the United States: 1982-2002, in Jordan report 20th anniversary: Accelerated development of vaccines 2002, A. National Institute of and D. Infectious, Editors. 2002, U.S. Department of Health and Human Services, National Institute of Allergy and Infectious Diseases: Washington, D.C. p. 58-71.
Reference Type
BACKGROUND
Esposito S, Bosis S, Pelucchi C, Begliatti E, Rognoni A, Bellasio M, Tel F, Consolo S, Principi N. Pediatrician knowledge and attitudes regarding human papillomavirus disease and its prevention. Vaccine. 2007 Aug 29;25(35):6437-46. doi: 10.1016/j.vaccine.2007.06.053. Epub 2007 Jul 16.
Reference Type
BACKGROUND
Schnatz PF, Humphrey K, O'Sullivan DM. Assessment of the perceptions and administration of the human papillomavirus vaccine. J Low Genit Tract Dis. 2010 Apr;14(2):103-7. doi: 10.1097/LGT.0b013e3181b240ca.
Reference Type
BACKGROUND
Kahn JA. Vaccination as a prevention strategy for human papillomavirus-related diseases. J Adolesc Health. 2005 Dec;37(6 Suppl):S10-6. doi: 10.1016/j.jadohealth.2005.08.018.
Reference Type
BACKGROUND
Ko EM, Missmer S, Johnson NR. Physician attitudes and practice toward human papillomavirus vaccination. J Low Genit Tract Dis. 2010 Oct;14(4):339-45. doi: 10.1097/LGT.0b013e3181dca59c.
Reference Type
BACKGROUND
Carroll AE, Bauer NS, Dugan TM, Anand V, Saha C, Downs SM. Use of a computerized decision aid for ADHD diagnosis: a randomized controlled trial. Pediatrics. 2013 Sep;132(3):e623-9. doi: 10.1542/peds.2013-0933. Epub 2013 Aug 19.
Reference Type
BACKGROUND
Carroll AE, Biondich P, Anand V, Dugan TM, Downs SM. A randomized controlled trial of screening for maternal depression with a clinical decision support system. J Am Med Inform Assoc. 2013 Mar-Apr;20(2):311-6. doi: 10.1136/amiajnl-2011-000682. Epub 2012 Jun 28.
Reference Type
BACKGROUND
Carroll AE, Biondich PG, Anand V, Dugan TM, Sheley ME, Xu SZ, Downs SM. Targeted screening for pediatric conditions with the CHICA system. J Am Med Inform Assoc. 2011 Jul-Aug;18(4):485-90. doi: 10.1136/amiajnl-2011-000088.
Reference Type
BACKGROUND
Fiks AG, Grundmeier RW, Mayne S, Song L, Feemster K, Karavite D, Hughes CC, Massey J, Keren R, Bell LM, Wasserman R, Localio AR. Effectiveness of decision support for families, clinicians, or both on HPV vaccine receipt. Pediatrics. 2013 Jun;131(6):1114-24. doi: 10.1542/peds.2012-3122. Epub 2013 May 6.
Reference Type
BACKGROUND
Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013 Aug 1;208(3):385-93. doi: 10.1093/infdis/jit192. Epub 2013 Jun 19.
Reference Type
BACKGROUND
Zimet GD, Rosberger Z, Fisher WA, Perez S, Stupiansky NW. Beliefs, behaviors and HPV vaccine: correcting the myths and the misinformation. Prev Med. 2013 Nov;57(5):414-8. doi: 10.1016/j.ypmed.2013.05.013. Epub 2013 May 31.
Reference Type
BACKGROUND
Rogers EM. A prospective and retrospective look at the diffusion model. J Health Commun. 2004;9 Suppl 1:13-9. doi: 10.1080/10810730490271449.
Reference Type
BACKGROUND
Glanzer, M. and A.R. Cunitz, Two storage mechanisms in free recall. Journal of Verbal Learning and Verbal Behavior, 1966. 5(4): p. 351-360.
Reference Type
BACKGROUND
Rogers, E.M., Diffusion of innovations. Vol. 4th 1995, New York: Free Press.
Reference Type
BACKGROUND
Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q. 2004;82(4):581-629. doi: 10.1111/j.0887-378X.2004.00325.x.
Reference Type
BACKGROUND
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50. doi: 10.1186/1748-5908-4-50.
Reference Type
BACKGROUND
Anand V, Biondich PG, Liu G, Rosenman M, Downs SM. Child Health Improvement through Computer Automation: the CHICA system. Stud Health Technol Inform. 2004;107(Pt 1):187-91.
Reference Type
BACKGROUND
Anand V, Carroll AE, Downs SM. Automated primary care screening in pediatric waiting rooms. Pediatrics. 2012 May;129(5):e1275-81. doi: 10.1542/peds.2011-2875. Epub 2012 Apr 16.
Reference Type
BACKGROUND
Biondich PG, Downs SM, Anand V, Carroll AE. Automating the recognition and prioritization of needed preventive services: early results from the CHICA system. AMIA Annu Symp Proc. 2005;2005:51-5.
Reference Type
BACKGROUND
Downs SM, Uner H. Expected value prioritization of prompts and reminders. Proc AMIA Symp. 2002:215-9.
Reference Type
BACKGROUND
Downs SM, Zhu V, Anand V, Biondich PG, Carroll AE. The CHICA smoking cessation system. AMIA Annu Symp Proc. 2008 Nov 6;2008:166-70.
Reference Type
BACKGROUND
Bauer, N.S., et al., Computer Decision Support to Improve Autism Screening and Care in Community Pediatric Clinics. Infants & Young Children, 2013. 26(4): p. 306-317.
Reference Type
BACKGROUND
Denzin, N.K. and Y.S. Lincoln, The Sage handbook of qualitative research. Vol. 4th. 2011, Thousand Oaks, CA: Sage.
Reference Type
BACKGROUND
Braun, V. and V. Clarke, Using thematic analysis in psychology. Qualitative research in psychology, 2006. 3(2): p. 77-101.
Reference Type
BACKGROUND
Fleiss JL, Tytun A, Ury HK. A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics. 1980 Jun;36(2):343-6.
Reference Type
BACKGROUND
Dixon BE, Kasting ML, Wilson S, Kulkarni A, Zimet GD, Downs SM. Health care providers' perceptions of use and influence of clinical decision support reminders: qualitative study following a randomized trial to improve HPV vaccination rates. BMC Med Inform Decis Mak. 2017 Aug 10;17(1):119. doi: 10.1186/s12911-017-0521-6.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Merck - 14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Parent-son-provider Decision-making About HPV Vaccination
NCT01284374
COMPLETED
High and Low Resource Interventions to Promote HPV Vaccines
NCT03824093
COMPLETED
NA
Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*
NCT07339163
NOT_YET_RECRUITING
PHASE1/PHASE2
Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
NCT00788164
COMPLETED
PHASE1
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
NCT06465914
ACTIVE_NOT_RECRUITING
PHASE3
Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
NCT02750202
COMPLETED
PHASE3
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
NCT05625633
RECRUITING
PHASE2/PHASE3
MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
NCT01769560
COMPLETED
NA
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
NCT05026138
RECRUITING
"Facts Tell… and With Stories Sell?" Combining Viewer-tailored Personal Human Papillomavirus (HPV) Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake
NCT06587243
RECRUITING
NA
A Multilevel Approach to Increasing HPV Vaccine Initiation Among Adolescents - Part 3
NCT04208269
COMPLETED
NA
PCOM2 - The Physician Communication Intervention, Version 2.0
NCT05336240
RECRUITING
NA
Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL
NCT02689726
TERMINATED
PHASE1
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
NCT00941889
COMPLETED
NA
Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL
NCT03911076
TERMINATED
PHASE2
Trial of a Social Marketing Campaign to Increase HPV Vaccination Among Mexican American Children
NCT02697396
ACTIVE_NOT_RECRUITING
Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial
NCT06367699
TERMINATED
NA
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
NCT05584332
TERMINATED
PHASE3
Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response
NCT03296397
UNKNOWN
PHASE3
Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
NCT02710851
UNKNOWN
PHASE2
Study of Treatment for HPV16+ ASC-US or LSIL
NCT03913117
RECRUITING
PHASE1
The STOP-HPV Scale Up Study
NCT06831383
NOT_YET_RECRUITING
NA
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children
NCT01995721
UNKNOWN
PHASE3
Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis
NCT00829608
WITHDRAWN
EARLY_PHASE1